Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02103881
Other study ID # HSR #13-3682
Secondary ID
Status Withdrawn
Phase Phase 4
First received February 20, 2014
Last updated July 20, 2017
Start date April 2014
Est. completion date June 2014

Study information

Verified date July 2017
Source Minneapolis Medical Research Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research study is being done to find out if one of two drugs, ketamine or haloperidol, is better for treating agitation. Agitation is a state of extreme emotional disturbance where patients can become physically aggressive or violent, endangering themselves and those who are caring for them. Often chemical substances or severe mental illness is involved in this level of agitation. Specifically, the investigators are interested in studying agitation that is treated in the prehospital setting by paramedics. This study's hypothesis is that ketamine is superior to haloperidol for treatment of agitation in the prehospital environment.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Clinical diagnosis of severe agitation in the prehospital environment

Exclusion Criteria:

- Prisoners

- Persons known to be younger than 18 years old

- Persons suspected to be younger than 18 years old

- Obviously gravid women

- Persons with profound agitation

- Persons who are unable to be transported to the treating facility

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ketamine
500 mg of intramuscular ketamine for severe pre-hospital agitation
Haloperidol
Haloperidol 10 mg intramuscular for severe prehospital agitation.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Minneapolis Medical Research Foundation

Outcome

Type Measure Description Time frame Safety issue
Primary Time from injection of drug to adequate sedation, defined as a score of 0 or less on the AMSS. The Altered Mental Status Scale (AMSS) is an integral ordinal scale evaluating both agitation and sedation with scores from -4 to +4. It was developed at our institution and has been internally and externally validated. This scale is a modified version of the Behavioral Activity Rating Scale with additional data points from the Observer's Assessment of Alertness Scale. Effectiveness of sedation will be defined as an AMS score less than or equal to 0.
AMSS will be determined by the treating paramedic, who will undergo training as a research associate prior to commencement of the study. Participants will be followed for the duration of agitation, an expected average of 2 hours.
2 hours
Secondary Number of participants intubated. Participants will be followed for the duration of agitation, an expected average of 2 hours. Enrolling paramedics or research associates in the Emergency Department will record if the patient is intubated. 2 hours
Secondary venous pH Venous blood will be drawn at one and ten minutes post sedation and assessed using point-of-care testing for pH. Enrolling paramedics or research associates in the Emergency Department will record the data. at one minutes and ten minutes post sedation
Secondary serum potassium Venous blood will be drawn at one and ten minutes post sedation and assessed using point-of-care testing for potassium concentration. Enrolling paramedics or research associates in the Emergency Department will record the data. at one minute and ten minutes post sedation
Secondary Total time the participant is a patient in the Emergency Department. Participants will be followed for the duration of agitation, an expected average of 2 hours. Enrolling paramedics or research associates in the Emergency Department will record both the time the patient arrives in the Emergency Department, and when they leave the Emergency Department. 2 hours
Secondary Number of patients admitted versus number of patients discharged. Participants will be followed for the duration of agitation, an expected average of 2 hours. Enrolling paramedics or research associates in the Emergency Department will record if the patient is admitted or discharged. 2 hours
Secondary venous lactate Venous blood will be drawn at one and ten minutes post sedation and assessed using point-of-care testing for lactate concentration. Enrolling paramedics or research associates in the Emergency Department will record the data. at one minute and ten minutes post sedation
Secondary Number of patients experiencing laryngospasm. Participants will be followed for the duration of agitation, an expected average of 2 hours. Enrolling paramedics or research associates in the Emergency Department will record if laryngospasm occurs. 2 hours
Secondary Number of patients experiencing dystonia. Participants will be followed for the duration of agitation, an expected average of 2 hours.Enrolling paramedics or research associates in the Emergency Department will record if dystonia occurs. 2 hours
See also
  Status Clinical Trial Phase
Completed NCT02525991 - Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting Phase 4
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Completed NCT01976754 - Safety Study of Dexmedetomidine in Septic Patients N/A
Completed NCT01217541 - Collaboration Between Department of Old Age Psychiatry and Nursing Homes N/A
Withdrawn NCT00786318 - Ziprasidone vs Standard Therapy for Agitated Patients in the ED Phase 4
Not yet recruiting NCT05974527 - Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department Phase 4
Not yet recruiting NCT05522647 - Detection of Risk Behaviors: Pilot Observational Study With Bedridden and Agitated Patients.
Recruiting NCT02590744 - Effects of Preoperative Using of Eye Patches on Prevention of Emergence Agitation After Cataract Surgery N/A
Recruiting NCT02164773 - Addition of Magnesium Sulfate to Caudal to Prevent Postoperative Emergence Agitation. Phase 4
Completed NCT01524367 - Effect of Single-dose Dexmedetomidine on Emergence Excitement in Adults With Nasotracheal Intubation After Orthognathic Surgery Phase 4
Completed NCT01501123 - Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient N/A
Completed NCT01021696 - Pain in Patients With Dementia and Behavioural Disturbances Phase 2/Phase 3
Recruiting NCT05397639 - Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Phase 3
Terminated NCT03044249 - A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression Phase 2
Completed NCT05165914 - Midazolam Effect on Agitation Postnasal Surgery N/A
Completed NCT04010305 - Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia Phase 1
Completed NCT02720705 - Transbucal Dexmedetomidine for Prevention of Sevoflurane Emergence Agitation in Pre-school Children Phase 2/Phase 3
Completed NCT02428283 - Scalp Nerve Block on Emergence Agitation Phase 4
Completed NCT00457366 - A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room Phase 4
Terminated NCT00315900 - Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia Phase 3